Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | GOT1 | P17174 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548266 | 1.00 | NOS1 (0.42) | NOS1AXLBACE1AHRKDM4E | |
| SCHEMBL14485973 | 0.73 | AXL (0.39) | NOS1AXLBACE1CYP1A2ALDH1A1 | |
| SCHEMBL30368877 | 0.73 | KDM4E (0.59) | AXLKDM4ECYP3A4CYP1A2TP53 | |
| SCHEMBL30343676 | 0.73 | TNF (0.53) | NOS1AXLBACE1KDM4ECYP3A4 | |
| SCHEMBL196671 | 0.73 | KDM4E (0.59) | AXLKDM4ECYP3A4CYP1A2TP53 | |
| SCHEMBL197053 | 0.73 | TNF (0.53) | NOS1AXLBACE1KDM4ECYP3A4 | |
| SCHEMBL6122152 | 0.71 | MAPT (0.38) | KDM4ECYP3A4CYP1A2TP53GOT1 | |
| SCHEMBL19001494 | 0.71 | NOS1 (0.42) | NOS1KDM4ECYP3A4CYP1A2TP53 | |
| SCHEMBL659324 | 0.71 | CYP3A4 (0.57) | KDM4ECYP3A4CYP1A2TP53GOT1 | |
| SCHEMBL19595854 | 0.71 | PSMD14 (0.40) | KDM4ECYP3A4CYP1A2TP53GOT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129168-A1 | TRIAZOLONE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-115785074-A | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-3596051-B1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2022-04-27 | — | — | EP | disclosed |
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| CN-111925331-A | Synthetic method of 6-bromophthalazine | 上海毕得医药科技有限公司 | 2020-11-13 | — | — | CN | disclosed |
| US-20200087281-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LIMITED (IN) | 2020-03-19 | — | — | US | disclosed |
| EP-2307400-B1 | INHIBITORS OF PI3 KINASE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2116538-B1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-7919504-B2 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-2167504-A2 | THIADIAZOLE MODULATORS OF PKB | Amgen, Inc (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20100063055-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-11 | — | — | US | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090298836-A1 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298836-A1 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298836-A1 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2116538-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009011871-A2 | THIADIAZOLE MODULATORS OF PKB | AMGEN INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011871-A2 | THIADIAZOLE MODULATORS OF PKB | AMGEN INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | SARM1, NNMT, NQO1 | NOS1 3565/4885AXL 4698/4885BACE1 78/4885 |
| US-20090298836-A1 | Thiadiazole modulators of PKB | PDK1, PDK2, MTOR | NOS1 1749/4885AXL 1782/4885BACE1 2772/4885 |
| US-20100063055-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | NR3C2, MC2R, NR5A1 | NOS1 1996/4885AXL 3786/4885BACE1 3603/4885 |
| US-20200087281-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | GPR119, GPR65, GPR88 | NOS1 2317/4885AXL 1344/4885BACE1 656/4885 |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | NOS1 3179/4885AXL 4700/4885BACE1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.